Upadacitinib
Back to searchMolecule Structure
Scientific Name
Upadacitinib
Description of the Drug
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15091
http://www.drugbank.ca/drugs/DB15091
Brand Name(s)
Rinvoq
Company Owner(s)
Abbvie Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Janus Kinase (JAK) | PROTEIN FAMILY | INHIBITOR | CHEMBL2363062 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL9991056 |
| DrugBank | DB15091 |
| PubChem | 58557659 |
| Nikkaji | J3.590.729G |
| BindingDB | 50503287 |
| DrugCentral | 5346 |
| ChemicalBook | CB53121345 |
| Guide to Pharmacology | 9246 |
| rxnorm | UPADACITINIB |
